Taiwan GLP-1 and Obesity-Related Development Companies
As of October 22, 2026, this table includes GLP-1 or weight-management drug, API and licensing-development projects at 7 Taiwan companies. [1] [2] [3] [4] [5] [6] [7]
The selected SNS851 program has entered Phase 1, and the CBL-514 plus tirzepatide program has Phase 2 IND clearance; API DMFs, license agreements and production-line development are kept separate from finished-drug approval. [1] [2] [3] [4] [5] [6] [7]
| Company | Ticker | Product / pipeline | Indication | Latest verified stage | Stage source and date | Most recent catalyst |
|---|---|---|---|---|---|---|
| ScinoPharm Taiwan Company source | 1789 | Weight-management injection / GLP-1 diabetes injection (names and codes undisclosed) | Weight management; diabetes | U.S. weight-management drug application filed; diabetes injection under review (jurisdiction unspecified) | 2026-08-17 Stage source submitted a U.S. drug application | — |
| Formosa Laboratories Company source | 4746 | Semaglutide injection (spelled Semagultide in source) | GLP-1 medicine; specific filing indications not disclosed | Formulation development; commercial and assembly lines under construction | 2026-03-13 Stage source 劑型開發進行中 | — |
| Chunghwa Chemical Synthesis & Biotech Company source | 1762 | Setmelanotide acetate API | Genetic obesity | Listed as U.S. DMF-registered API 41490; not a finished-drug approval | 2026-09-16 Stage source SETMELANOTIDE ACETATE | — |
| Oneness Biotech Company source | 4743 | SNS851 (siRNA; not a GLP-1 agonist) | Obesity and metabolic disease-related weight-management development | Australian Phase 1; single dosing completed and multiple dosing started in August 2026 | 2026-08-21 Stage source 2026.08啟動 | The August 2026 presentation planned completion of SNS851 dosing in Q4 2026; completion is not verified. 2026-08-21 Source 預定2026.Q4完成所有受試者給藥 |
| Caliway Biopharmaceuticals Company source | 6919 | CBL-514 plus tirzepatide (CBL-0201WR) | Reduction of abdominal subcutaneous fat in overweight or obese adults | Phase 2 IND cleared by FDA; first dosing not inferred | 2026-08-31 Stage source CBL-0201WR Ph2 study: IND已核准 | — |
| Lotus Pharmaceutical Company source | 1795 | Semaglutide injection (Wegovy / Ozempic 2 mg generic partnership) | Specific filing indications not disclosed in this annual-report passage | License and supply agreement with Adalvo signed; clinical phase not specified | 2026-10-22 Stage source License and Supply Agreement with Adalvo | — |
| Polaris Group Company source | 6550 | Semaglutide / tirzepatide API and formulation pipeline | Diabetes; obesity / weight management | API and formulation development pipeline; clinical phase undisclosed | 2025-12-11 Stage source 具備針劑/口服製劑開發與生產能力 | — |
Scope and public-document limits
API, finished-drug and licensing roles and stages are distinct. Product names, filing indications, clinical phases and confirmed approval dates absent from the cited sources remain unfilled.